-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Vapotherm's HVT 2.0 System Overcomes Regulatory Hurdles for Entry Into South America's Largest Health Care Market
Vapotherm's HVT 2.0 System Overcomes Regulatory Hurdles for Entry Into South America's Largest Health Care Market
EXETER, N.H., Feb. 29, 2024 /PRNewswire/ -- Vapotherm, Inc. (OTCQX: VAPO), ("Vapotherm" or the "Company"), a global medical technology company specializing in the development and commercialization of its proprietary Vapotherm high-velocity therapy products for patients of all ages experiencing respiratory distress, is pleased to announce the regulatory approval of the HVT 2.0 system in Brazil.
The therapeutic respiratory devices market in Brazil, valued at USD 302.4 million in 2022, is anticipated to grow at a CAGR of 6.5% from 2023 to 2030.1 With approximately 8 million cases of COPD and a growing aging population, there is an increasing demand for respiratory devices in the country. COPD stands as a significant health concern in Brazil, ranking sixth leading cause of death.2
Joe Army, Vapotherm's President and Chief Executive Officer expressed his optimism, stating, "I'm excited about emerging market growth for Vapotherm. In the third quarter of 2023, we posted 25% global capital equipment revenue growth compared to the third quarter of 2022, partly driven by sales in Brazil. With the approval and subsequent launch of HVT 2.0 in Brazil, we look forward to establishing ourselves as a frontline solution in Latin America."
The mobility of the HVT 2.0 platform, ease of use, multi-functionality, and the upgraded design which freed the device from requiring an external source of compressed air makes HVT 2.0 an ideal respiratory support device for care of patients ranging from pediatric to the elderly. These features facilitate optimal patient care in the most advanced hospitals as well as resource constrained environments.
With the approval of the new system in Brazil, Vapotherm is launching a new Portuguese website and social media campaign. The Company attended in the XXVIII Brazilian Congress of Intensive Care Medicine, the largest event of its kind in Latin America, to collaborate with approximately three thousand clinicians.
About Vapotherm
Vapotherm, Inc. (OTCQX: VAPO) is a publicly traded developer and manufacturer of advanced respiratory technology based in Exeter, New Hampshire, USA. The Company develops innovative, comfortable, non-invasive technologies for respiratory support of patients with chronic or acute breathing disorders. Over 4.2 million patients have been treated with the use of Vapotherm high velocity therapy systems. For more information, visit .
Vapotherm high velocity therapy is mask-free non-invasive respiratory support and is a front-line tool for relieving respiratory distress—including hypercapnia, hypoxemia, and dyspnea. It allows for the fast, safe treatment of undifferentiated respiratory distress with one tool. The HVT 2.0 and Precision Flow systems' mask-free interface delivers optimally conditioned breathing gases, making it comfortable for patients and reducing the risks and care complexities associated with mask therapies. While being treated, patients can talk, eat, drink and take oral medication.
Legal Notice Regarding Forward-Looking Statements
This press release contains forward-looking statements under the Private Securities Litigation Reform Act of 1995, including statements about the Company's business and growth prospects in Brazil. In some cases, you can identify forward-looking statements by terms such as "expect," "anticipate," "continue," "plan," "intend," "will," or "typically," or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words, and the use of future dates. Each forward-looking statement is subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statement. Applicable risks and uncertainties include the failure of the Company's products to achieve market acceptance or significant market growth in Brazil and the other risks and uncertainties included under the heading "Risk Factors" in Vapotherm's Annual Report on Form 10-K for the fiscal year ended December 31, 2023, as filed with the SEC on February 22, 2024, and in its subsequent filings with the SEC. The forward-looking statements contained in this press release reflect Vapotherm's views as of the date hereof, and Vapotherm does not assume and specifically disclaims any obligation to update any forward-looking statements whether as a result of new information, future events or otherwise, except as required by law.
Investor Relations Contacts:
John Landry, SVP & CFO, [email protected], +1 (603) 658-0011
1
2
SOURCE Vapotherm, Inc.
EXETER, N.H., Feb. 29, 2024 /PRNewswire/ -- Vapotherm, Inc. (OTCQX: VAPO), ("Vapotherm" or the "Company"), a global medical technology company specializing in the development and commercialization of its proprietary Vapotherm high-velocity therapy products for patients of all ages experiencing respiratory distress, is pleased to announce the regulatory approval of the HVT 2.0 system in Brazil.
新罕布什尔州埃克塞特,2024年2月29日 /PRNewswire/ — Vapotherm, Inc.(OTCQX:VAPO)(“Vapotherm” 或 “公司”)是一家全球医疗技术公司,专门为所有年龄段的呼吸窘迫患者开发和商业化其专有的Vapotherm高速治疗产品,欣然宣布巴西监管部门批准了HVT 2.0系统。
The therapeutic respiratory devices market in Brazil, valued at USD 302.4 million in 2022, is anticipated to grow at a CAGR of 6.5% from 2023 to 2030.1 With approximately 8 million cases of COPD and a growing aging population, there is an increasing demand for respiratory devices in the country. COPD stands as a significant health concern in Brazil, ranking sixth leading cause of death.2
巴西的治疗性呼吸设备市场在2022年价值3.024亿美元,预计从2023年到2030年将以6.5%的复合年增长率增长。1 随着大约800万例慢性阻塞性肺病病例和日益老龄化的人口老龄化,该国对呼吸设备的需求不断增加。慢性阻塞性肺病是巴西的重大健康问题,在死亡原因中排名第六。2
Joe Army, Vapotherm's President and Chief Executive Officer expressed his optimism, stating, "I'm excited about emerging market growth for Vapotherm. In the third quarter of 2023, we posted 25% global capital equipment revenue growth compared to the third quarter of 2022, partly driven by sales in Brazil. With the approval and subsequent launch of HVT 2.0 in Brazil, we look forward to establishing ourselves as a frontline solution in Latin America."
Vapotherm总裁兼首席执行官乔·阿米表示乐观,他说:“我对Vapotherm的新兴市场的增长感到兴奋。2023年第三季度,我们公布的全球资本设备收入与2022年第三季度相比增长了25%,部分原因是巴西的销售。随着HVT 2.0的批准以及随后在巴西的推出,我们期待将自己确立为拉丁美洲的一线解决方案。”
The mobility of the HVT 2.0 platform, ease of use, multi-functionality, and the upgraded design which freed the device from requiring an external source of compressed air makes HVT 2.0 an ideal respiratory support device for care of patients ranging from pediatric to the elderly. These features facilitate optimal patient care in the most advanced hospitals as well as resource constrained environments.
HVT 2.0 平台的移动性、易用性、多功能性以及使设备无需外部压缩空气源的升级设计使 HVT 2.0 成为护理从儿科到老年患者的理想呼吸支持设备。这些功能有助于在最先进的医院和资源有限的环境中提供最佳的患者护理。
With the approval of the new system in Brazil, Vapotherm is launching a new Portuguese website and social media campaign. The Company attended in the XXVIII Brazilian Congress of Intensive Care Medicine, the largest event of its kind in Latin America, to collaborate with approximately three thousand clinicians.
随着巴西新系统的批准,Vapotherm正在启动一个新的葡萄牙语网站和社交媒体活动。该公司参加了第二十八届巴西重症监护医学大会,这是拉丁美洲同类活动中规模最大的会议,与大约三千名临床医生合作。
About Vapotherm
关于 Vapotherm
Vapotherm, Inc. (OTCQX: VAPO) is a publicly traded developer and manufacturer of advanced respiratory technology based in Exeter, New Hampshire, USA. The Company develops innovative, comfortable, non-invasive technologies for respiratory support of patients with chronic or acute breathing disorders. Over 4.2 million patients have been treated with the use of Vapotherm high velocity therapy systems. For more information, visit .
Vapotherm, Inc.(场外交易代码:VAPO)是一家上市的先进呼吸技术的开发商和制造商,总部位于美国新罕布什尔州埃克塞特。该公司开发创新、舒适、无创的技术,为慢性或急性呼吸障碍患者提供呼吸支持。使用Vapotherm高速治疗系统已经治疗了超过420万名患者。欲了解更多信息,请访问。
Vapotherm high velocity therapy is mask-free non-invasive respiratory support and is a front-line tool for relieving respiratory distress—including hypercapnia, hypoxemia, and dyspnea. It allows for the fast, safe treatment of undifferentiated respiratory distress with one tool. The HVT 2.0 and Precision Flow systems' mask-free interface delivers optimally conditioned breathing gases, making it comfortable for patients and reducing the risks and care complexities associated with mask therapies. While being treated, patients can talk, eat, drink and take oral medication.
Vapotherm 高速疗法是无口罩的非侵入性呼吸支持,是缓解呼吸困难(包括高碳酸血症、低氧血症和呼吸困难)的一线工具。它允许使用一种工具快速、安全地治疗无差别的呼吸窘迫。HVT 2.0 和 Precision Flow 系统的无口罩接口可提供处于最佳状态的呼吸气体,使患者感到舒适,并降低了与口罩疗法相关的风险和护理复杂性。在接受治疗期间,患者可以说话、吃东西、喝水和服用口服药物。
Legal Notice Regarding Forward-Looking Statements
关于前瞻性陈述的法律声明
This press release contains forward-looking statements under the Private Securities Litigation Reform Act of 1995, including statements about the Company's business and growth prospects in Brazil. In some cases, you can identify forward-looking statements by terms such as "expect," "anticipate," "continue," "plan," "intend," "will," or "typically," or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words, and the use of future dates. Each forward-looking statement is subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statement. Applicable risks and uncertainties include the failure of the Company's products to achieve market acceptance or significant market growth in Brazil and the other risks and uncertainties included under the heading "Risk Factors" in Vapotherm's Annual Report on Form 10-K for the fiscal year ended December 31, 2023, as filed with the SEC on February 22, 2024, and in its subsequent filings with the SEC. The forward-looking statements contained in this press release reflect Vapotherm's views as of the date hereof, and Vapotherm does not assume and specifically disclaims any obligation to update any forward-looking statements whether as a result of new information, future events or otherwise, except as required by law.
本新闻稿包含根据1995年《私人证券诉讼改革法》做出的前瞻性陈述,包括有关公司在巴西的业务和增长前景的声明。在某些情况下,您可以通过 “期望”、“预期”、“继续”、“计划”、“打算”、“将” 或 “通常” 等术语来识别前瞻性陈述,或者这些术语的否定词或其他类似表述来识别前瞻性陈述,尽管并非所有前瞻性陈述都包含这些词语以及未来日期的使用。每份前瞻性陈述都存在风险和不确定性,这些风险和不确定性可能导致实际结果与此类陈述中表达或暗示的结果存在重大差异。适用的风险和不确定性包括公司的产品未能在巴西获得市场接受或实现显著的市场增长,以及Vapotherm于2024年2月22日向美国证券交易委员会提交的截至2023年12月31日财年的10-K表年度报告以及随后向美国证券交易委员会提交的文件中 “风险因素” 标题下包含的其他风险和不确定性。本新闻稿中包含的前瞻性陈述反映了Vapotherm截至本文发布之日的观点,除非法律要求,否则Vapotherm不假设并明确表示不承担任何更新任何前瞻性陈述的义务,无论是由于新信息、未来事件还是其他原因。
Investor Relations Contacts:
John Landry, SVP & CFO, [email protected], +1 (603) 658-0011
投资者关系联系人:
约翰·兰德里,高级副总裁兼首席财务官,[email protected],+1 (603) 658-0011
1
2
1
2
SOURCE Vapotherm, Inc.
来源 Vapotherm, Inc.
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧